Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linezolid vs vancomycin for post-neurosurgical CNS infections
ChiCTR2000041052Phase 4Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jan 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in bacterial meningitis, ventriculitis and Central nervous system infection comparing linezolid + meropenem with Control: vancomycin + meropenem (2 arms). Primary endpoint: Control rate of intracranial infection. Started Jan 2021; status: recruiting.
02
Drugs
linezolidvancomycin
03
Conditions
bacterial meningitisventriculitisCentral nervous system infection
Beyond the preview
Go deeper on ChiCTR2000041052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041052.